Please assess the completion status of the following clinical trial:

Trial Title: Study of Oxaliplatin, Irinotecan, and S-1 in Gastric Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically confirmed advanced, recurrent or metastatic adenocarcinoma of stomach (stage IV by primary tumor, regional nodes, metastasis(TNM) staging system)~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2~* More than 3 months expected life span~* Measurable lesion by RECIST criteria version 1.1~* Palliative chemotherapy naive~* Adequate organ functions~* Participants must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policy of the hospital~Exclusion Criteria:~* Positive Her2 status on participants' cancer tissue.~* Any prior 2 years or concurrent malignancy other than non-melanoma skin cancer, in situ cancer of uterine cervix, or papillary or follicular thyroid cancer.~* Participants who had received radiation therapy for target lesions 4 weeks before study enrollment~* Participants who had received major surgery 4 weeks before study enrollment~* Participants with active infection, severe heart disease, uncontrollable hypertension or diabetes mellitus, myocardial infarction during the preceding 12 months, pregnancy, or breast feeding~* Participants with central nervous system(CNS) metastases~* Participants with peripheral sensory neuropathies with impaired functional activities~* Participants with gastrointestinal obstruction or bleeding inducing mal-absorption of oral chemotherapeutic agents.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oxaliplatin, Irinotecan, S-1(OIS) (Type: EXPERIMENTAL): triple combination with oxaliplatin, irinotecan, and S-1.~Treatment will be delivered as a 2-week cycle.~1. Oxaliplatin 65 mg/m2 iv on day 1~2. Irinotecan 135 mg/m2 iv on day 1~3. S-1 80 mg/m2/day on day 1-7

Based on this trial design, predict the completion outcome and termination type (if applicable).